{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:15:09Z","timestamp":1778505309114,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2023J011592"],"award-info":[{"award-number":["2023J011592"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2025QNA121"],"award-info":[{"award-number":["2025QNA121"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J011333"],"award-info":[{"award-number":["2024J011333"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"crossref","award":["3502Z202373098"],"award-info":[{"award-number":["3502Z202373098"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program for High-Quality Health Development of Xiamen","award":["2024GZL-QN103"],"award-info":[{"award-number":["2024GZL-QN103"]}]},{"name":"Science and Technology Program for High-Quality Health Development of Xiamen","award":["2024GZL-ZD03"],"award-info":[{"award-number":["2024GZL-ZD03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11928-2","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:44:54Z","timestamp":1778503494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitexin inhibits renal cell carcinoma progression by targeting Galectin-1-mediated glycolytic metabolism"],"prefix":"10.1007","volume":"53","author":[{"given":"Xinjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"11928_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P (2019) Epidemiology of Renal Cell Carcinoma. Eur Urol 75:74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036","journal-title":"Eur Urol"},{"key":"11928_CR2","doi-asserted-by":"publisher","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch E, Gao J, Rathmell WK (2014) Renal cell carcinoma. BMJ 349:g4797. https:\/\/doi.org\/10.1136\/bmj.g4797","journal-title":"BMJ"},{"key":"11928_CR3","doi-asserted-by":"publisher","first-page":"189241","DOI":"10.1016\/j.bbcan.2024.189241","volume":"1880","author":"R Deng","year":"2025","unstructured":"Deng R, Zong G-f, Wang X, Yue B-j, Cheng P, Tao R-z, Li X, Wei Z-h, Lu Y (2025) Promises of natural products as clinical applications for cancer. Biochimica et Biophysica Acta (BBA) -. Reviews Cancer 1880:189241. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189241","journal-title":"Reviews Cancer"},{"key":"11928_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/10408398.2020.1753165","volume":"61","author":"Y Peng","year":"2021","unstructured":"Peng Y, Gan R, Li H, Yang M, McClements DJ, Gao R, Sun Q (2021) Absorption, metabolism, and bioactivity of vitexin: recent advances in understanding the efficacy of an important nutraceutical. Crit Rev Food Sci Nutr 61:1049\u20131064. https:\/\/doi.org\/10.1080\/10408398.2020.1753165","journal-title":"Crit Rev Food Sci Nutr"},{"key":"11928_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s43440-024-00664-8","volume":"77","author":"Q Yang","year":"2025","unstructured":"Yang Q, Huan R, Meng D, Qi J, Xia L (2025) Progress in the study of anti-tumor effects and mechanisms of vitexin. Pharmacol Rep 77:124\u2013134. https:\/\/doi.org\/10.1007\/s43440-024-00664-8","journal-title":"Pharmacol Rep"},{"key":"11928_CR6","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.18632\/oncotarget.22890","volume":"9","author":"M Bhardwaj","year":"2018","unstructured":"Bhardwaj M, Cho HJ, Paul S, Jakhar R, Khan I, Lee SJ, Kim BY, Krishnan M, Khaket TP, Lee HG et al (2018) Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells. Oncotarget 9:3278\u20133291. https:\/\/doi.org\/10.18632\/oncotarget.22890","journal-title":"Oncotarget"},{"issue":"9","key":"11928_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms17091566","volume":"17","author":"JM Cousin","year":"2016","unstructured":"Cousin JM, Cloninger MJ (2016) The role of Galectin-1 in cancer progression, and synthetic multivalent systems for the study of Galectin-1. Int J Mol Sci 17(9):1566. https:\/\/doi.org\/10.3390\/ijms17091566","journal-title":"Int J Mol Sci"},{"key":"11928_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5230\/jgc.2024.24.e25","volume":"24","author":"Z Pan","year":"2024","unstructured":"Pan Z, Xu G, Zhang Y, Wu M, Yu J, He X, Zhang W, Hu J (2024) Galectin-1 promotes gastric carcinoma progression and cisplatin resistance through the NRP-1\/c-JUN\/Wee1 Pathway. J Gastric Cancer 24:300\u2013315. https:\/\/doi.org\/10.5230\/jgc.2024.24.e25","journal-title":"J Gastric Cancer"},{"key":"11928_CR9","doi-asserted-by":"publisher","first-page":"106984","DOI":"10.1016\/j.isci.2023.106984","volume":"26","author":"AM Rudjord-Levann","year":"2023","unstructured":"Rudjord-Levann AM, Ye Z, Hafkenscheid L, Horn S, Wiegertjes R, Nielsen MAI, Song M, Mathiesen CBK, Stoop J, Stowell S et al (2023) Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1. iScience 26:106984. https:\/\/doi.org\/10.1016\/j.isci.2023.106984","journal-title":"iScience"},{"key":"11928_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41419-022-05024-z","volume":"13","author":"MR Guda","year":"2022","unstructured":"Guda MR, Tsung AJ, Asuthkar S, Velpula KK (2022) Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism. Cell Death Dis 13:574. https:\/\/doi.org\/10.1038\/s41419-022-05024-z","journal-title":"Cell Death Dis"},{"issue":"4","key":"11928_CR11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/HEP.0000000000001391","volume":"83","author":"T Nguyen","year":"2026","unstructured":"Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu DSK, Raman SS, Chiang J (2026) Galectin-1 modulates glycolysis through a GM1-galactose-dependent pathway to promote hyperthermia resistance in HCC. Hepatology 83(4):808\u2013826","journal-title":"Hepatology"},{"key":"11928_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12967-023-04167-7","volume":"21","author":"L Chen","year":"2023","unstructured":"Chen L, Li X, Deng Y, Chen J, Huang M, Zhu F, Gao Z, Wu L, Hong Q, Feng Z et al (2023) The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII. J Transl Med 21:323. https:\/\/doi.org\/10.1186\/s12967-023-04167-7","journal-title":"J Transl Med"},{"key":"11928_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-024-01965-5","volume":"23","author":"W Ge","year":"2024","unstructured":"Ge W, Wang Y, Quan M, Mao T, Bischof EY, Xu H, Zhang X, Li S, Yue M, Ma J et al (2024) Activation of the PI3K\/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Mol Cancer 23:48. https:\/\/doi.org\/10.1186\/s12943-024-01965-5","journal-title":"Mol Cancer"},{"key":"11928_CR14","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.3390\/ijms26125853","volume":"26","author":"L Lu","year":"2025","unstructured":"Lu L, Deng Y, Li J, Feng X, Zou H (2025) Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions. Int J Mol Sci 26:5853","journal-title":"Int J Mol Sci"},{"key":"11928_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.biochi.2020.05.006","volume":"175","author":"JH Lee","year":"2020","unstructured":"Lee JH, Mohan CD, Shanmugam MK, Rangappa S, Sethi G, Siveen KS, Chinnathambi A, Alahmadi TA, Alharbi SA, Basappa S et al (2020) Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway. Biochimie 175:58\u201368. https:\/\/doi.org\/10.1016\/j.biochi.2020.05.006","journal-title":"Biochimie"},{"key":"11928_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12943-024-02108-6","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang J, Chen S, Lin N, Xu S, Miao J, Zhang J, Chen C, Yuan X, Xie Z et al (2024) Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Mol Cancer 23:196. https:\/\/doi.org\/10.1186\/s12943-024-02108-6","journal-title":"Mol Cancer"},{"key":"11928_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/ijms26010265","volume":"26","author":"MO Abah","year":"2025","unstructured":"Abah MO, Ogenyi DO, Zhilenkova AV, Essogmo FE, Ngaha Tchawe YS, Uchendu IK, Pascal AM, Nikitina NM, Rusanov AS, Sanikovich VD et al (2025) Innovative Therapies Targeting Drug-Resistant Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC). Int J Mol Sci 26:265","journal-title":"Int J Mol Sci"},{"key":"11928_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ctrv.2013.07.007","volume":"40","author":"L Astorgues-Xerri","year":"2014","unstructured":"Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S (2014) Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 40:307\u2013319. https:\/\/doi.org\/10.1016\/j.ctrv.2013.07.007","journal-title":"Cancer Treat Rev"},{"key":"11928_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1074\/mcp.M112.020701","volume":"12","author":"O Masui","year":"2013","unstructured":"Masui O, White NMA, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R et al (2013) Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteom 12:132\u2013144. https:\/\/doi.org\/10.1074\/mcp.M112.020701","journal-title":"Mol Cell Proteom"},{"key":"11928_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43094-024-00757-4","volume":"11","author":"L Li","year":"2025","unstructured":"Li L, Huang X, Chen Y, Liu J, Qiao Y, Fan W, Zhang P, Yan X, Chen M (2025) Natural products targeting ubiquitination to combat kidney fibrosis. Future J Pharm Sci 11:13. https:\/\/doi.org\/10.1186\/s43094-024-00757-4","journal-title":"Future J Pharm Sci"},{"key":"11928_CR21","doi-asserted-by":"publisher","first-page":"1381467","DOI":"10.3389\/fonc.2024.1381467","volume":"14","author":"F Chen","year":"2024","unstructured":"Chen F, Xiao M, Hu S, Wang M (2024) Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer. Front Oncol 14:1381467. https:\/\/doi.org\/10.3389\/fonc.2024.1381467","journal-title":"Front Oncol"},{"key":"11928_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.20517\/cdr.2023.79","volume":"7","author":"Y \u0130lhan","year":"2024","unstructured":"\u0130lhan Y, Melek A, Ammad Ahmad F, Mehmet Tolgahan H, Brigitta B, Marzia A, Luciano S (2024) Regulation of Nrf2\/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications. Cancer Drug Resist 7:8. https:\/\/doi.org\/10.20517\/cdr.2023.79","journal-title":"Cancer Drug Resist"},{"key":"11928_CR23","doi-asserted-by":"publisher","first-page":"1195500","DOI":"10.3389\/fendo.2023.1195500","volume":"14","author":"H Zhu","year":"2023","unstructured":"Zhu H, Wang X, Lu S, Ou K (2023) Metabolic reprogramming of clear cell renal cell carcinoma. Front Endocrinol (Lausanne) 14:1195500. https:\/\/doi.org\/10.3389\/fendo.2023.1195500","journal-title":"Front Endocrinol (Lausanne)"},{"key":"11928_CR24","doi-asserted-by":"publisher","first-page":"1664292","DOI":"10.3389\/fcell.2025.1664292","volume":"13","author":"J Yang","year":"2025","unstructured":"Yang J, Miao D, Li X, Zhao C, Tan D, Wu S, Lu F, Shi J, Lv Q, Ruan H et al (2025) Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications. Front Cell Dev Biol 13:1664292. https:\/\/doi.org\/10.3389\/fcell.2025.1664292","journal-title":"Front Cell Dev Biol"},{"key":"11928_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3892\/br.2021.1455","volume":"15","author":"M Ogorevc","year":"2021","unstructured":"Ogorevc M, Strikic A, Tomas SZ (2021) Determining the immunohistochemical expression of GLUT1 in renal cell carcinoma using the HSCORE method. Biomed Rep 15:79. https:\/\/doi.org\/10.3892\/br.2021.1455","journal-title":"Biomed Rep"},{"key":"11928_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3892\/ol.2020.11917","volume":"20","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Han F, Zhang X, Zhou C, Huang D (2020) Aryl hydrocarbon receptor nuclear translocator promotes the proliferation and invasion of clear cell renal cell carcinoma cells potentially by affecting the glycolytic pathway. Oncol Lett 20:56. https:\/\/doi.org\/10.3892\/ol.2020.11917","journal-title":"Oncol Lett"},{"key":"11928_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41435-025-00336-4","volume":"26","author":"K Wang","year":"2025","unstructured":"Wang K, Kong F, Han X, Zhi Y, Wang H, Ren C, Wang H (2025) Integrative multi-omics reveal NSUN2 facilitates glycolysis and histone lactylation-driven immune evasion in renal carcinoma. Genes Immun 26:312\u2013323. https:\/\/doi.org\/10.1038\/s41435-025-00336-4","journal-title":"Genes Immun"},{"key":"11928_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jri.2011.04.004","volume":"90","author":"I Fischer","year":"2011","unstructured":"Fischer I, Jeschke U, Friese K, Daher S, Betz AG (2011) The role of galectin-1 in trophoblast differentiation and signal transduction. J Reprod Immunol 90:35\u201340. https:\/\/doi.org\/10.1016\/j.jri.2011.04.004","journal-title":"J Reprod Immunol"},{"issue":"4","key":"11928_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cells9040806","volume":"9","author":"YL Su","year":"2020","unstructured":"Su YL, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Chiang PH, Chen YT, Kang CH, Cheng YT (2020) Galectin-1 Overexpression Activates the FAK\/PI3K\/AKT\/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival. Cells 9(4):806. https:\/\/doi.org\/10.3390\/cells9040806","journal-title":"Cells"},{"key":"11928_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/bjc.2013.828","volume":"110","author":"NM White","year":"2014","unstructured":"White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM (2014) Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF\/mTOR signaling axis. Br J Cancer 110:1250\u20131259. https:\/\/doi.org\/10.1038\/bjc.2013.828","journal-title":"Br J Cancer"},{"key":"11928_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"11928_CR32","doi-asserted-by":"publisher","first-page":"108774","DOI":"10.1016\/j.bioorg.2025.108774","volume":"163","author":"S Yan","year":"2025","unstructured":"Yan S, Wang L, Liu D, Qin H, Du C, Chai J, Liu Y, Chen Y, Liu H, Jin T (2025) Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential. Bioorg Chem 163:108774. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108774","journal-title":"Bioorg Chem"},{"key":"11928_CR33","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.Mct-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt E, Soares HP, Sinnet-Smith J (2014) Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther 13:2477\u20132488. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0330","journal-title":"Mol Cancer Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11928-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11928-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:44:55Z","timestamp":1778503495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11928-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11928"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11928-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"738"}}